Metabolomics-Based Clinical Efficacy and Effect on the Endogenous Metabolites of Tangzhiqing Tablet, a Chinese Patent Medicine for Type 2 Diabetes Mellitus with Hypertriglyceridemia
Table 2
The changes comparison of clinical characteristics before and after treatment in three groups (mean ± S.D.).
Variable
TZQ Group (n=15)
Placebo Group (n=15)
Acarbose Group (n=16)
Before treatment
After treatment
Before treatment
After treatment
Before treatment
After treatment
BMI (kg/m2)
26.99±3.17
25.41±3.44
28.56±3.87
28.53±3.44
25.90±2.27
25.69±2.33
Waistline (cm)
95.43±11.24
92.77±10.29
100.23±8.36
100.60±8.29
94.87±8.44
93.63±7.74
HbA1c (%)
7.64±0.81
7.52±1.18
7.59±1.03
7.67±0.74
7.25±0.79
7.16±0.92
FINS (mIU/L)
16.64±8.65
14.28±8.29
15.00±7.07
15.73±7.77
15.10±14.57
10.42±4.97
FBG (mmol/L)
7.44±1.17
7.85±2.11
7.75±1.07
7.98±1.43
7.62±1.17
7.27±1.22
OGTT2hBG (mmol/L)
13.96±4.02
13.72±4.89
13.76±3.15
13.90±4.65
13.91±4.68
12.03±4.30
TG (mmol/L)
1.52±0.61
1.88±1.51
2.06±1.05
2.17±1.24
2.35±1.38
1.81±1.18
TC (mmol/L)
4.92±0.70
4.99±0.93
4.87±0.82
4.95±1.05
4.74±0.78
4.56±0.90
LDL (mmol/L)
2.86±0.52
2.91±0.70
2.87±0.61
2.85±0.79
2.59±0.63
2.52±0.73
HDL (mmol/L)
1.38±0.39
1.30±0.40
1.17±0.25
1.17±0.30
1.22±0.35
1.24±0.40
Note: data were analyzed using paired t-test or covariance analysis. p< 0.05 (compared with the same group before treatment, paired t-test), p < 0.05 (compared with placebo group, covariance analysis). FBG: fasting blood glucose; OGTT 2hBG: oral glucose tolerance test 2 h blood glucose; HbA1c: glycosylated hemoglobin; BMI: body mass index; TC: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol.
